Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia

Andreas Holstein (1) , Michael Hahn (1) , Olaf Patzer (1) , Angela Seeringer (2) , Peter Kovacs (3) , Julia Stingl (2)

1 First Department of Medicine, Klinikum Lippe-Detmold
2 Institute of Pharmacology of Natural Products & Clinical Pharmacology
3 Interdisciplinary Center of Clinical Research

Mots clés: Type 2 diabetes mellitus; Hypoglycemia; Sulfonylureas; CYP2C9 variants

Andreas Holstein, Michael Hahn, Olaf Patzer, Angela Seeringer, Peter Kovacs, et al.. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. European Journal of Clinical Pharmacology, 2011, 67 (5), pp.471-476. ⟨10.1007/s00228-010-0976-1⟩. ⟨hal-00657591⟩